, Tracking Stock Market Picks
Enter Symbol:
Vanda Pharmaceuticals Inc. (VNDA) [hlAlert]

up 178.83 %

Vanda Pharmaceuticals Inc. (VNDA) rated Buy with price target $22 by Caris & Company

Posted on: Friday,  May 2, 2008  8:25 AM ET by Caris & Company

Caris & Company rated Buy Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) on 05/02/2008, when the stock price was $4.30.
Since then, Vanda Pharmaceuticals Inc. has gained 178.84% as of 01/27/2016's recent price of $11.99.
If you would have followed this Caris & Company's recommendation on VNDA, you would have gained 178.83% of your investment in 2826 days.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.

Caris & Company, an investment bank created by a diverse group of leading Wall Street professionals. We are founded on the basic principle that Wall Street requires a different type of organization: One that offers objective, conflict-free research, acute focus on customer service, broad institutional coverage, and an unwavering commitment to increasing the value of our clients' portfolios. Quite simply, our goal is to generate solid investment ideas for our clients. We offer a unique, differentiated, conflict-free research perspective on large, mid, and small capitalization companies in four growth oriented verticals: Health Care, Technology, Energy, and Consumer.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/2/2008 8:25 AM Buy
4.30 22.00
as of 12/24/2008
1 Week down  -10.47 %
1 Month up  17.50 %
3 Months up  23.68 %
1 YTD up  88.00 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy